MOTIVATION LETTER The Conjunctive Consolidation Threshold model proposes a tripartite pharmacological mechanism for preventing reward-memory encoding in addiction. Three sole-authored preprints on OSF and Zenodo formalize this framework, including a Bayesian population dynamics specification and a clinical trial architecture. ODE/RK45 validation demonstrated an encoding probability reduction from 0.855 to 0.122, an 85.8 percent decrease, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This work has received endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is filed for Q3 2026. The Wits Future Research Leaders Fellowship requires a PhD and typically more than ten years of post-PhD experience. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, a German equivalent of 1.9, and I am not yet enrolled in an MSc programme. I am applying for October 2026 start at MUG or Graz in Austria. I do not meet the doctoral degree requirement or the post-PhD experience threshold specified for this fellowship. I am an independent researcher based in Lagos, Nigeria, with no postgraduate supervision history and no sustained record of peer-reviewed publications in indexed journals. My three preprints are on preprint servers, and one review article is under review at Neuroscience and Biobehavioral Reviews. I have not yet attracted competitive research funding. I am withdrawing this application and will instead target early-career and pre-PhD fellowships that do not require a doctoral degree. Programmes such as the UNESCO Researchers Fellowship in Japan or LMIC-focused independent researcher grants are more appropriate for my current career stage. I will reapply to Wits when I hold a PhD and have established a stronger publication and funding record. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience: no existing pharmacological intervention prevents the encoding of reward-memory associations during the consolidation window. Current treatments target craving, withdrawal, or receptor blockade after memory formation is complete. The CCT model proposes simultaneous modulation of three systems, dopamine D1 receptor signaling, NMDA receptor-dependent plasticity, and endocannabinoid retrograde signaling, during the 6-hour post-exposure consolidation window. The formal mathematical specification, available on OSF, defines the conjunctive threshold as a three-dimensional manifold where simultaneous subthreshold activation of all three pathways prevents long-term potentiation in the nucleus accumbens core. Validation used ODE/RK45 numerical integration with parameters drawn from published electrophysiology data. Encoding probability dropped from 0.855 to 0.122, an 85.8 percent reduction. The triple combination showed super-additivity of 12.8 percentage points beyond the sum of individual effects. Bayesian MCMC estimation with PyMC confirmed posterior probability of 0.94 that the triple combination exceeds any dual combination. All five pre-registered hypotheses H1 through H5 were confirmed. A co-authored paper on alcohol use disorder is under review at Alcohol, Elsevier. Three computational platforms support this research. IMPRINT screens addiction liability using pharmacokinetic and pharmacodynamic features. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to drug-protein interaction networks, with a hERG cardiotoxicity MVP completed. GATE evaluates safety of BCI neural-stimulation protocols and is released under Apache 2.0. These platforms are built in Python with scipy, numpy, PyMC, Ripser, Gudhi, and RDKit, and deployed on Supabase and Postgres. The CCT model has direct relevance to addiction burden in Nigeria and across sub-Saharan Africa. Opioid and methamphetamine use is rising in West African urban centers, yet no region-specific pharmacological interventions exist. The clinical trial architecture specified in the third preprint uses a Bayesian adaptive design with population dynamics parameters calibrated to Nigerian demographic data. This design reduces required sample size by 40 percent compared to frequentist alternatives, making trials feasible in resource-limited settings. Future work includes experimental validation in rodent models through a planned collaboration with Kent Berridge at Michigan, and a first-in-human safety trial using the GATE platform for neural-stimulation safety evaluation. The provisional patent filed in Q3 2026 covers the core tripartite architecture and its Bayesian dosing algorithm. SHORT ESSAY: RESEARCH INDEPENDENCE AND LEADERSHIP I have conducted all CCT model development as an independent researcher in Lagos, Nigeria, without institutional affiliation or dedicated laboratory funding. The three preprints, the mathematical specification, and the Bayesian clinical trial architecture were produced without a supervisor or co-author. I built the computational platforms IMPRINT, TOPOLOGIX, and GATE from scratch, writing all code and deploying all infrastructure. The TOPOLOGIX hERG cardiotoxicity MVP required learning persistent homology and simplicial complex theory independently, then implementing it with Ripser and Gudhi. The GATE platform for BCI safety evaluation was released under Apache 2.0 and is available for community use. Leadership is demonstrated through the provisional patent filing on the CCT core architecture, which required navigating the Nigerian patent system without legal counsel. I secured endorsements from four senior researchers at Michigan, Harvard, Princeton, and NYU by cold-emailing my preprints and engaging in technical correspondence. Samuel Gershman at Harvard provided my arXiv endorsement. These relationships were built entirely through the quality of the written work, not through prior connections. As National Product Manager at Synthcare since March 2026, I lead a team responsible for product strategy across Nigeria. This role requires coordinating with regulatory bodies, managing cross-functional teams, and making data-driven decisions under budget constraints. The clinical pharmacist role at Ramset Pharmacy from January to March 2026 provided direct patient care experience that informs the translational direction of the CCT model. SHORT ESSAY: INTERNATIONAL COLLABORATION AND NETWORKS The CCT model has attracted attention from four laboratories outside Nigeria. Kent Berridge at the University of Michigan, whose work on incentive salience defined the field, has reviewed the foundational preprint and provided feedback on the dopamine D1 component. Samuel Gershman at Harvard endorsed my arXiv submission after reviewing the mathematical specification. Nathaniel Daw at Princeton and Marcelo Mattar at NYU have both corresponded on the Bayesian population dynamics and the clinical trial architecture. These interactions occurred through email and video calls, without travel or conference attendance. The co-authored paper under review at Alcohol, Elsevier, represents a collaboration with researchers studying alcohol use disorder mechanisms. This paper applies the CCT framework to alcohol-specific reward-memory encoding and includes data from rodent models. The collaboration began when I contacted the lead author after reading their published work on alcohol-induced plasticity in the nucleus accumbens. The GATE platform for BCI neural-stimulation safety evaluation is released under Apache 2.0 to encourage international adoption and contribution. The platform is designed to be modular, allowing researchers in any country to add their own safety criteria and stimulation parameters. The TOPOLOGIX platform for topological drug-protein interaction analysis is available on GitHub and has been forked by two users whose identities are unknown. Future collaboration plans include a rodent validation study with Berridge's laboratory at Michigan, contingent on funding. A first-in-human safety trial would require partnership with a clinical research organization in Nigeria or South Africa. The Bayesian adaptive trial design in the third preprint is specifically calibrated for low-resource settings and could be implemented with local ethics board approval and minimal infrastructure. CHECKLIST - [ ] Confirm eligibility: Wits Future Research Leaders Fellowship requires PhD and >10 years post-PhD experience. Applicant does not meet either criterion. - [ ] Withdraw application or do not submit. Do not proceed with this programme. - [ ] Identify alternative early-career fellowships: UNESCO Researchers Fellowship (Japan), LMIC-focused independent researcher grants, pre-PhD programmes. - [ ] Verify that the programme website does not list exceptions for independent researchers without PhD. - [ ] Prepare materials for alternative programmes that match current career stage. EDITOR NOTES - Eligibility is the primary risk. The programme requires a PhD and typically more than ten years post-PhD experience. The applicant holds a B.Pharm and is not enrolled in any graduate programme. Applying would waste time and may create a negative record. - The applicant should verify whether the Wits programme has any early-career or pre-PhD track not mentioned in the captured programme description. The URL provided may have additional details not included in the prompt. - The applicant should insert the exact name of the alternative fellowship they plan to target, as this document currently recommends withdrawal without specifying a concrete next step. The UNESCO Researchers Fellowship and LMIC grants are suggestions from the strategy notes but are not confirmed as open or appropriate. - The applicant's age (29) and career stage (pre-PhD, independent researcher) are strong signals for early-career programmes. The profile contains substantial independent research output that would be competitive for pre-PhD fellowships. This should be the focus, not senior fellowships. - The provisional patent filing date of Q3 2026 is in the future relative to the application date. The applicant should confirm whether the patent has been filed or is still pending, and adjust all references accordingly.